Much of the work that is being done in nano biotechnology is academic and at the government level.
We will use an already established mouse model of Alzheimer’s Disease for pre-clinical trials.
We have identified the intellectual property from the U.S. Department of Energy and the public sector.
In collaboration with the following academic institutions, we have obtained a patent license agreement for the method to manufacture our nanoparticle delivery system complex.
nano-ADEPT will be customized for targeted delivery to the Alzheimer’s affected area of the brain.
We will obtain Amyloid beta protein and Tau antibodies from an antibody database, then attach these to the surface of our nano carrier.
We will utilize an international patent to achieve nano-carrier controllable and sustained drug release over several weeks at a time.